CUPID (NCT04726033) is a phase I trial enrolling 15 patients with prostate cancer that is evaluating the adverse events, pharmacokinetics, biodistribution, and radiation dosimetry of TLX592 (targeting PSMA) using 64Cu as the imaging agent. This evidence concerns the gene FOLH1 and Familial prostate cancer.